2 completed, 1 withdrawn. 3 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 3 | Completed 2, Withdrawn 1 |
Follow Roche Global Development: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Targeting PD-L1 and TIGIT in Tumors With Tertiary Lymphoid Structures Atezolizumab 1200 mg IV, Tiragolumab 600 mg IV - Metastatic Cancer Lung, Advanced Lung Cancer | Phase 2 | Withdrawn | Gustave Roussy, Cancer Campus, Grand Paris | 2025-01-30 | 2026-03-23 | |
| Study of Oxaliplatin and Xeloda and Cetuximab as First Line Treatment for Metastatic or Unresectable Gastric or Gastroesophageal Junction Cancer oxaliplatin, capecitabine - Gastric Cancer, Esophageal Cancer | Phase 2 | Completed | University of Southern California | 75 | 2004-12-28 | 2026-07-30 |
| Tarceva and Capecitabine for Pancreatic Cancer Capecitabine, OSI-774 - Pancreatic Cancer, Neoplasm Metastasis | Phase 2 | Completed | Dana-Farber Cancer Institute | 32 | 2003-10-01 | 2009-11-02 |
Esophageal Neoplasms (1) · Lung Neoplasms (1) · Neoplasm Metastasis (1) · Pancreatic Neoplasms (1) · Stomach Neoplasms (1)
Capecitabine (2) · Erlotinib Hydrochloride (1) · Oxaliplatin (1) · Tiragolumab (1) · atezolizumab (1)
United States (2)
Matthew Kulke, MD (1) · Syma Iqbal, M.D. (1)
2023 (1)